Article
Gastroenterology & Hepatology
Feng Su, Noel S. Weiss, Lauren A. Beste, Andrew M. Moon, Ga-Young Jin, Pamela Green, Kristin Berry, George N. Ioannou
Summary: This study indicates that liver cancer screening is significantly associated with a reduction in liver cancer-related mortality in patients with hepatitis B infection.
JOURNAL OF HEPATOLOGY
(2021)
Review
Virology
Yashasavi Sachar, Mayur Brahmania, Renumathy Dhanasekaran, Stephen E. Congly
Summary: Chronic hepatitis B (CHB) infection is a significant risk factor for developing hepatocellular carcinoma (HCC), and screening high-risk patients with CHB is recommended to improve outcomes. However, there is inconsistency in screening recommendations, and identifying high-risk patients would optimize resource utilization.
Article
Gastroenterology & Hepatology
Jonggi Choi, Nabihah Tayob, Young-Suk Lim
Summary: This study evaluated the performance of the parametric empirical Bayes (PEB) longitudinal AFP screening algorithm in patients with hepatitis B compared to AFP surveillance with a fixed threshold. The results showed that the PEB algorithm improved the accuracy of hepatocellular carcinoma (HCC) screening in patients with hepatitis B compared to AFP alone, without additional cost or inconvenience to patients.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Jeffrey V. Lazarus, Camila A. Picchio, Massimo Colombo
Summary: Hepatitis C virus (HCV) is a major cause of hepatocellular carcinoma (HCC) worldwide, and its carcinogenic potential is mediated through various mechanisms. Early detection, prevention, and treatment of HCV are important for reducing HCC-related mortality. People who inject drugs (PWID) play a significant role in HCV transmission, and an integrated approach is needed to eliminate HCV as a global health threat.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Jiaoxia He, Zhongling Zheng, Tingting Liu, Yupei Ao, Yixuan Yang, Huaidong Hu
Summary: This study used proteomics to screen salivary markers for hepatitis B-associated liver cancer. The expression of ORM1 in saliva was found to be significantly higher in HCC patients, and the combination of salivary ORM1 and AFP showed reasonable diagnostic efficacy for hepatocellular carcinoma.
SCIENTIFIC REPORTS
(2022)
Article
Health Care Sciences & Services
Anh Le Tuan Nguyen, Lei Si, John S. Lubel, Nicholas Shackel, Kwang Chien Yee, Mark Wilson, Jane Bradshaw, Kerry Hardy, Andrew John Palmer, Christopher Leigh Blizzard, Barbara de Graaff
Summary: HCC surveillance using biannual ultrasound +/- AFP, as recommended in Australia, was found to be cost-effective.
BMC HEALTH SERVICES RESEARCH
(2023)
Article
Oncology
Furong Sun, Zhifei Liu, Bingyuan Wang
Summary: The study aimed to explore the characteristics of low-level viremia patients and prognostic factors after curative hepatectomy. The results showed that patients in the low-level viremia group had smaller tumor diameters and lower rates of tumor recurrence compared to the high HBV DNA group.
Article
Oncology
Chiara Rocha, Erin H. Doyle, Chip A. Bowman, M-Isabel Fiel, Ashley E. Stueck, Nicolas Goossens, Kian Bichoupan, James F. Crismale, Jasnit Makkar, Sara Lewis, Ponni V. Perumalswami, Thomas D. Schiano, Yujin Hoshida, Myron Schwartz, Andrea D. Branch, Neal Patel
Summary: Successful treatment of hepatitis C reduces liver inflammation and fibrosis, but patients are still at risk of developing hepatocellular carcinoma. Risk factors for post-SVR HCC include non-Caucasian race, smoking, age over 60, low albumin level, elevated AST/ALT ratio, and low platelet count. AFP may be a promising marker for post-SVR HCC risk.
Article
Medicine, General & Internal
Siyu Liu, Liyang Sun, Lanqing Yao, Hong Zhu, Yongkang Diao, Mingda Wang, Hao Xing, Wan Yee Lau, Mingcheng Guan, Timothy M. Pawlik, Feng Shen, Min Xu, Xiangmin Tong, Tian Yang
Summary: This study compared the diagnostic performance of different serum biomarkers alone or in combination for HCV-associated HCC. PIVKA-II showed the best predictive performance, and the combination of PIVKA-II + AFP also had good predictive performance.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Yi-Hao Yen, Kwong-Ming Kee, Wei-Feng Li, Yueh-Wei Liu, Chih-Chi Wang, Tsung-Hui Hu, Ming-Chao Tsai, Chih-Yun Lin
Summary: This study found that 51.2% of HCC patients had elevated AFP levels, and this proportion remained stable from 2011 to 2020. The proportion of early-stage HCC decreased during this period, while the proportion of NBNC-HCC increased. Advanced tumor stage, severe underlying liver disease, viral etiology, and female gender were associated with elevated AFP levels in HCC patients.
Review
Obstetrics & Gynecology
Francesco Marasciulo, Irene Passerini, Anna Fichera, Federico Ferrari, Franco E. Odicino, Federico Prefumo
Summary: Hepatocellular carcinoma is the most common primary malignant liver tumor, which typically occurs in the context of chronic liver disease. Diagnosis and treatment of hepatocellular carcinoma during pregnancy can be challenging, but better maternal outcomes are associated with early diagnosis in high-risk asymptomatic women or through abnormal maternal serum AFP screening.
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
(2023)
Article
Oncology
Jihye Lim, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Seong Gyu Hwang, Han Chu Lee, Yeonjung Ha
Summary: This study validated the clinical usefulness of the CAGE-B score in a large number of Asian patients treated with long-term entecavir or tenofovir, providing the basis for the reappraisal of hepatocellular carcinoma surveillance strategies.
Review
Gastroenterology & Hepatology
Daniel Q. Q. Huang, Amit G. Singal, Fasiha Kanwal, Pietro Lampertico, Maria Buti, Claude B. Sirlin, Mindie H. Nguyen, Rohit Loomba
Summary: In this review, the authors discuss the current status of hepatocellular carcinoma (HCC) surveillance and the challenges that remain. They highlight the changing causes of liver disease and the need for strategies to improve the utilization and quality of surveillance. The underutilization of surveillance is attributed to limited disease awareness, knowledge gaps, and difficulty in identifying high-risk individuals. Non-alcoholic fatty liver disease and alcohol-associated liver disease are emerging as significant causes of HCC-related death, posing unique barriers to surveillance. The sensitivity of current surveillance approaches is limited, especially for patients with cirrhosis or obesity.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
(2023)
Review
Gastroenterology & Hepatology
Hira Hanif, Mukarram Jamat Ali, Ammu T. Susheela, Iman Waheed Khan, Maria Alejandra Luna-Cuadros, Muzammil Muhammad Khan, Daryl Tan-Yeung Lau
Summary: Alpha-fetoprotein (AFP) is a tumor marker for hepatocellular carcinoma (HCC), but its utility is limited. However, combining AFP with other novel biomarkers can improve its accuracy. Additionally, increased AFP levels may be associated with liver diseases and other non-hepatic disorders.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Review
Biochemistry & Molecular Biology
Endrit Shahini, Giuseppe Pasculli, Antonio Giovanni Solimando, Claudio Tiribelli, Raffaele Cozzolongo, Gianluigi Giannelli
Summary: HCC is the most common primary liver cancer, and its mortality rate is increasing globally. Early diagnosis is critical, and combining novel biomarkers with traditional ones can enhance HCC detection sensitivity. Developing new diagnostic tools and prognostic scores may improve patients' survival.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)